Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

It’s Time to Dominate Direct Mail: AmeriLife Launches Highly Anticipated LeadStar Direct

AmeriLife

LeadStar, the proprietary, private leads platform created with and exclusively for AmeriLife -affiliated agents, announced today that it has officially launched LeadStar Direct, a best-in-class direct mail lead campaign and CRM solution that’s set to transform the direct mail game for health and life agents nationwide – and just in time for Medicare’s Annual Enrollment Period (AEP). “With compliance top of mind for every agent this year, the launch of LeadStar Direct fulfills AmeriLife’s continued promise to our partners and their agents to arm them with the best tools to confidently and reliably grow their books of business,” said William DeCourcy, senior vice president of Growth Marketing and Customer Acquisition for AmeriLife. “Alongside LeadStar Marketplace, we’re incredibly excited to deliver a best-in-class combination of lead generation solutions to market.” Originally announced during Medicarians 2023 and developed in partnership with RGI Solutions, LeadStar Direct provides agents with continuously optimized direct mail campaigns powered by an intuitive shopping experience that allows them to go from sign-up to mailing in just one day. The platform is also regulation ready and 100% compliant with all federal and state-level marketing requirements. Alongside precision targeting capabilities and enhanced data and selection filtering, agents won’t needlessly spend money on targets that don’t meet their qualifications to better maximize their response rates. “In today’s environment, direct mail campaigns require a simpler, more secure and more targeted approach,” added Ovi Vitas, Chief Marketing Officer for AmeriLife. “With LeadStar Direct, agents can be sure that their investments are well spent on a platform designed to deliver smarter, more successful campaigns.” Join LeadStar Direct for an Exclusive Launch Event on Aug. 10 With LeadStar Direct now live, the team is hosting a public launch webinar at 2 p.m. ET on Thursday, Aug. 10, to dive deep into the platform’s features alongside an esteemed group of partners and power uses. To register and learn more about LeadStar Direct, click here. ### About AmeriLife AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as the leader in developing, marketing, and distributing life and health insurance, annuities and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For more than 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers served through a distribution network of over 300,000 insurance agents and advisors and 120 marketing organizations and insurance agency locations nationwide. For more information, visit AmeriLife.com, and follow AmeriLife on Facebook and LinkedIn. About LeadStar LeadStar is the industry’s preeminent enterprise leads program that delivers the compliant, reliable and performative leads that today’s health and life insurance agents need to grow their books of business and maximize their success. Powered by AmeriLife and exclusively for the company’s affiliated agents, LeadStar’s suite of solutions includes LeadStar Marketplace, LeadStar Connect and LeadStar Direct. For more information, contact an AmeriLife-affiliated marketing company or visit LeadStarHub.com. Contact Details Media Jeff Maldonado +1 321-297-1112 jmaldonado@amerilife.com Partnership Inquiries Patrick Nichols +1 727-726-0726 pnichols@amerilife.com Company Website https://amerilife.com/

August 08, 2023 09:00 AM Eastern Daylight Time

Navis Clinical Laboratories Joins Nashville Area Health Services Community With Grand Opening of New Headquarters

Navis Clinical Laboratories

Navis Clinical Laboratories ( navisclinical.com ), a leading provider of laboratory services that is making groundbreaking strides in health care solutions for substance use disorder and other disease states, celebrated its official grand opening with a ribbon cutting ceremony at its new corporate headquarters located in the Greater Nashville area city of Franklin, Tenn. Focused on innovative, cutting-edge research and development, Navis provides laboratory drug testing solutions and molecular and clinical blood testing for healthcare providers to aid in the diagnosis, treatment, management and prevention of substance use disorder, mental health conditions, chronic pain, and common comorbid acute and chronic diseases, including HIV/AIDS, hepatitis, sexually transmitted infections (STIs), urinary tract infections (UTIs), respiratory infections and antibiotic resistant infections. President and CEO Richard Stripp, Ph.D., who was joined by Navis leadership, employees, friends and family, shared his excitement about Navis’ future. “We’re delighted to be in Nashville, the health services capital of the U.S., and to have the opportunity to bring business and jobs to the area. We have a very aggressive growth strategy, and this is just the beginning for us. We have a national footprint serving clients nationwide, and this move will help facilitate our evolution into a one-stop shop for our clients and allow us to deliver services to patients who really need our help.” Lori Odom, Senior Vice President of Economic Development, Nashville Area Chamber of Commerce, opened the ceremony with a warm welcome to Navis, which joins the area’s robust and diverse health care community of more than 500 health care companies, making it the largest industry in the region. “Nashville is known as Music City, but it is also Healthcare City. Our mission is to create economic prosperity by facilitating leadership and partnership with companies, and Navis is a great example of what that can accomplish,” said Odom. “At Navis, we understand that behind everything we do is a human being whose life is directly impacted by the services we provide,” said Dr. Stripp. “Many patients we serve have complex health conditions. Navigating the healthcare system to find care that treats the whole patient rather than just a single illness is often a challenge. We advocate for those patients by developing solutions that empower healthcare providers to provide exceptional care, improve outcomes and save lives.” Navis launched in February of this year and currently owns three state-of-the-art laboratories located in New York, Washington and Massachusetts, allowing it to provide services nationally to healthcare practices. Dr. Stripp originally founded the New York laboratory location as American Forensic Toxicology Services. About Navis Clinical Laboratories Navis Clinical Laboratories ( navisclinical.com ) believes in advocating for those who can’t advocate for themselves, helping them navigate through challenging times. Focused on innovative, cutting-edge research and development to aid in the diagnosis, treatment, management and prevention of disease, Navis provides toxicology, clinical blood and molecular testing for healthcare providers to help reduce suffering and save the lives of people with substance use disorder, mental health conditions, chronic pain and other acute and chronic diseases. Contact Details Kim Kudasik kkudasik@navisclinical.com

August 08, 2023 06:00 AM Central Daylight Time

Image

News Release

Therma Bright CEO says permanent insurance codes for Venowave could be a game changer

Therma Bright Inc

Therma Bright Inc CEO Rob Fia discusses the imminent decision on permanent codes for Venowave, its compact, lightweight deep vein thrombosis (DVT) prevention device, with Proactive's Stephen Gunnion. Fia said the importance of securing these codes from the Centers for Medicare and Medicaid Services (CMS) lies in easier reimbursement processes, streamlining billing, and facilitating distribution. Venowave is a groundbreaking compression device that actively moves blood from the calf to the heart, FDA-approved for preventing blood clots and addressing issues like deep vein thrombosis, chronic venous insufficiency, and varicose veins. Unlike pneumatic devices in the market, Venowave employs waveform technology, setting it apart. Fia highlighted the potential market size, estimated at over a billion dollars, and the significant advantage of holding the first permanent code for a compression device. The CEO also elaborated on the expanding US distribution network, including partnerships with a Medicare Advantage healthcare provider and Texas-based doctors' groups. These partnerships offer direct engagement with payers, facilitating billing and reimbursement. Moreover, Therma Bright is also finalizing agreements with a distributor in Connecticut. The anticipated outcome of securing permanent codes for Venowave could revolutionize the industry, simplifying processes and enhancing market reach, Fia said. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

August 07, 2023 01:54 PM Eastern Daylight Time

Video

News Release

Avricore Health's HealthTab expands globally with UK feasibility study

Avricore Health

Avricore Health CEO Hector Bremner tells Proactive's Stephen Gunnion that HealthTab has been selected for a UK-based feasibility study, marking an important international expansion. Avricore Health has achieved success in Canada with HealthTab, the company's leading pharmacy-based platform for testing and health data management. Now, in partnership with Barts Hart Centre and HEART UK, the platform will be used to support NHS England's efforts to enhance community pharmacy-driven care for cardiovascular disease. The success of the NHS's Health Check program, which conducted over a million opportunistic blood pressure checks, revealed the need for advanced screening methods. Bremner emphasized the increasing role of community pharmacies in global healthcare systems, offering on-demand care beyond emergency rooms. The feasibility study will initially focus on five locations in London, with plans to rapidly scale up to 50 and beyond. Avricore Health envisions HealthTab as a global solution, with consistent demand across markets, and the UK's supportive pharmacy infrastructure and population size make it an ideal starting point. Bremner expressed optimism about HealthTab's potential to revolutionize healthcare delivery internationally. Contact Details Proactive Studio +1 347-449-0879 na-editorial@proactiveinvestors.com

August 07, 2023 01:37 PM Eastern Daylight Time

Video

Immunic CEO says Q2 results "couldn't be better"

Immunic Inc

Immunic Inc (NASDAQ:IMUX) president and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive following the release of the Munich-based biotechnology company's second-quarter financial results and a corporate update. Dr. Vitt says that the performance of the business during Q2 "couldn't have been better", highlighting what he calls "scientifically a very good quarter and uneventful on the more general financial side." He goes on to give more detail about the progress achieved with Immunic's prospective multiple sclerosis (MS) and celiac disease treatments during the quarter, noting the preclinical data for its most advanced molecule IMU-838 that was published in the Journal of Medicinal Chemistry and positive results From Phase 1b Clinical Trial of IMU-856 in celiac disease. Looking to the future, Dr. Vitt expects more trial data to be released in the fall of this year, and reiterates that the company is fully funded into Q4 of 2024. Contact Details Proactive United States +1 347-449-0879 action@proactiveinvestors.com

August 07, 2023 09:50 AM Eastern Daylight Time

Video

HKBU unveils treatment potential of herbal extract compound isoliquiritigenin for pancreatic cancer

Hong Kong Baptist University

HONG KONG SAR - Media OutReach - 7 August 2023 - A research led by scientists of Hong Kong Baptist University (HKBU) found that isoliquiritigenin (ISL), a flavonoid isolated from the Chinese herbal medicine licorice, can inhibit pancreatic cancer progression. It may also enhance the efficacy of conventional chemotherapeutic drugs in treating pancreatic cancer. It is the first time that a research group reported the anticancer potential of ISL in treating pancreatic cancer. The research findings have been published in the international academic journal Phytomedicine and recently presented in the Annual Congress of the European Association for Cancer Research 2023 in Torino, Italy. Pancreatic cancer as the "silent killer" Pancreatic cancer is often called the "silent killer" as most patients experience little or no symptoms until it has advanced and spread. According to the Global Cancer Statistics 2020 released by the International Agency for Research on Cancer, the mortality-to-incidence ratio of pancreatic cancer is greater than 93%. It is the fourth leading cause of cancer deaths in Hong Kong. Whipple (pancreaticoduodenectomy) operation is the only available curative treatment of pancreatic cancer. However, only 20% of patients are suitable for resection and the recurrence rate is high. In non-resectable cases and metastatic pancreatic cancer patients, the chemotherapeutic drug gemcitabine (GEM) remains the mainstream treatment. Nevertheless, GEM-based combination therapy exhibits profound chemoresistance with serious systemic toxicity. Gancao extract identified as anticancer agent In the search for alternative treatments for pancreatic cancer, a research team led by Dr Joshua Ko Ka-Shun, Associate Professor, Teaching and Research Division of the School of Chinese Medicine at HKBU, screened all the potential pancreatic cancer disease markers and the biological therapeutic activities of phytochemicals from the medicinal plant Glycyrrhiza glabra (licorice, or Gancao in Chinese) using network pharmacology. Network pharmacology is an emerging discipline which systematically catalogue the molecular interactions of a drug molecule in a living cell using complex computations, and has become an important tool in botanical drug discovery. Using this approach, the team identified ISL as a potential anticancer agent for the treatment of pancreatic cancer. With a series of cell experiments, the team demonstrated that ISL suppressed the growth and induced apoptosis (programmed cell death) of pancreatic cancer cells. In two human pancreatic cancer cell lines applied with 12.5 μM and 25 μM concentrations of ISL respectively, their cell survival rates were about 50% and 80% lower than the control cells with no ISL applied. The percentage of late stage apoptosis in the two cell lines was 11% and 13% respectively, compared to less than 5% in the control cells. Inhibits cancer progression with fewer side effects "ISL possesses a unique property of inhibiting pancreatic cancer progression through the blockade of autophagy, which is a natural process where the body's cells clean out damaged or unnecessary components. The blockade of late-stage autophagy in our experiments results in cancer cell death," said Dr Ko. The research team further employed a mice tumor model to investigate the efficacy of ISL in inhibiting pancreatic cancer cell growth in vivo. The mice were divided into three groups with GEM (GEM group), ISL (ISL group) and no treatment agent (control group) applied. The ISL group was further divided into two sub-groups treated with 30mg/kg and 60mg/kg of ISL. On the 21st day of the experiment, the tumor volumes of the control group and the GEM group were1000 mm3 and 400 mm3 respectively. The tumor volumes of the two ISL sub-groups treated with 30mg/kg and 60mg/kg of ISL were about 500 mm3 and 300 mm3 respectively. The results showed that ISL demonstrated treatment effects comparable to that of GEM. Meanwhile, compared with GEM, ISL showed fewer side effects in mice including neutropenia (drop in white blood cell count), anemia and body weight loss. Enhances effects of chemotherapies Current first-line chemotherapeutic drugs for pancreatic cancer, such as GEM and 5-fluorouracil (5-FU), are frequently associated with chemoresistance. It is because these drugs induce autophagy which favours the growth of cancer cells, and thus jeopardises their treatment effects. To explore ISL's potential in counteracting the chemoresistance of GEM and 5-FU, the research team set up experiments with pancreatic cancer cells treated with GEM or 5-FU alone, and GEM or 5-FU together with ISL. The growth inhibition rate of pancreatic cancer cells applied with GEM and ISL together is 18% higher than using GEM only, while the growth inhibition rate using 5-FU and ISL together is 30% higher than 5-FU only. The results showed that ISL can enhance the treatment effects of chemotherapeutic drugs by blocking autophagy, which is conducive to the death of cancer cells. "The findings in this study open a new avenue for developing ISL as a novel autophagy inhibitor in the treatment of pancreatic cancer. We hope to collaborate with other research partners to further evaluate the effectiveness and potential clinical application of ISL in treating pancreatic cancer," said Dr Ko. Contact Details Communication and Public Relations Office Christina Wu christinawu@hkbu.edu.hk

August 07, 2023 09:00 AM Eastern Daylight Time

Image

Ilika CEO says Cirtec deal an "absolutely fantastic validation"

Ilika PLC

Ilika PLC (AIM:IKA, OTCQX:ILIKF) CEO Graeme Purdy speaks to Thomas Warner from Proactive after announcing the signing of a 10-year agreement with US complex medical device company Cirtec Medical to provide Ilika's Stereax solid-state batteries. The deal establishes an exclusive relationship with Cirtech for the use of Stereax batteries in medical devices and features an initial period of profit sharing, later transitioning into a royalty on net sales, ensuring mutual benefit. He refers to the deal as an "absolutely fantastic verification and validation" of Ilika's business model. Purdy suggests that despite Stereax's potential suitability for use in sectors such as the Internet of Things, he's always been clear that the initial commercial focus for Ilika during Stereax's early life will be on medical devices. He also mentions what he calls exciting progress with the other side of the business, the much larger Goliath Electric Vehicle (EV) batteries, and signals more positive developments in the future. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

August 07, 2023 08:21 AM Eastern Daylight Time

Video

C4X Discovery focused and funded after £15.95mln strategic divestment

C4X Discovery Holdings PLC

C4X Discovery Holdings PLC (AIM:C4XD) chief business officer Bhavna Hunjan and chief scientific officer Nick Ray speak to Thomas Warner from Proactive after the drug discovery company announced what it calls the strategic divestment of its Orexin-1 receptor antagonist programme to Indivior PLC (LSE:INDV) for £15.95mln. In the divestment, C4X Discovery has sold the proprietary rights to its Orexin-1 antagonist programme for substance use disorders, including the lead candidate INDV-2000, to Indivior. This allows the company to crystallise the value of the programme, providing non-diluted funding for its future platform strategy. Bhavna Hunjan explains that the deal offers an opportunity to realise the value of the programme sooner, aligning with their focus on immuno-inflammatory diseases and providing valuable non-dilutive funding for the company. Nick Ray adds that the divestment is in line with their strategy to move forward as an immuno-inflammatory focused company. He reveals more about the company's pipeline, saying that good progress is being made toward the clinic with their lead programme and have several early-stage projects that will be further developed and disclosed to the public when ready. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

August 07, 2023 08:01 AM Eastern Daylight Time

Video

News Release

MIRA Pharmaceuticals debuts on the Nasdaq with plans to revolutionize medicinal CBD and THC

MIRA Pharmaceuticals

MIRA Pharmaceuticals CEO Erez Aminov, CEO joined Proactive's Stephen Gunnion as the company started trading on the Nasdaq under the ticker symbol 'MIRA'. Aminov said MIRA is making groundbreaking advancements in the cannabis industry with the development of a synthetic marijuana analog that aims to revolutionize medicinal cannabis usage. This new molecular entity, created using patented technology, offers the benefits of THC and CBD without their typical side effects, such as paranoia, anxiety, and impaired cognition. Clinical studies at John Hopkins Medical School revealed that this compound not only alleviates anxiety and chronic pain but also enhances cognition by 100% in animal studies. MIRA's synthetic THC is intended for medicinal use and is undergoing FDA approval. The pharmaceutical-grade version aims to provide a clean, safe, and effective option for patients, allowing them access to cannabis-based relief without the impurities and toxicity associated with plant-based marijuana. Moreover, MIRA's product stands out by being unscheduled, making it available to federal employees and veterans. The company's mission is to address unmet needs, such as anxiety and cognitive impairment in early-stage dementia patients, with minimal side effects. MIRA Pharmaceuticals raised $8.9 million in the IPO, which will be primarily directed towards accelerating toxicology and clinical research to bring the revolutionary drug to market. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

August 03, 2023 02:40 PM Eastern Daylight Time

Video

1 ... 96 97 98 99 100 ... 302